 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...2021222324252627282930...858859» |
- || Cosentyx (secukinumab) / Novartis, Rituxan (rituximab) / Roche, Aimovig (erenumab-aooe) / Amgen, Novartis
Review, Journal: Pyoderma Gangrenosum Associated With Iatrogenic Interleukin 17A Blockade: A Report of Two Cases and (Pubmed Central) - Oct 27, 2024
More recently, certain medications were implicated, including TNF-alpha inhibitors, rituximab, and IL-17A inhibitors, such as secukinumab, where the development of PG is held to represent a cutaneous immune adverse effect...One patient received the anti-calcitonin gene-related peptide targeted therapy, erenumab, for migraine prophylaxis...We documented a microenvironment enriched in IL-17A, emphasizing that the blockade impacts the functionality of the receptor as opposed to a quantitative reduction in IL-17A production by T cells. Qualitative functional IL-17A blockade could result in a paradoxical increase in IL-23, a pro-inflammatory cytokine that may contribute to the influx of neutrophils pathogenetically implicated in PG.
- | Ibrance (palbociclib) / Pfizer
Journal: Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ?18: DxCARTES study. (Pubmed Central) - Oct 27, 2024
The efficacy of neoadjuvant treatment with letrozole plus palbociclib does not seem to depend on pretreatment RS for patients with RS ?18. However, around half of patients with HR-positive/HER2-negative early breast cancer with an RS 26-100 at baseline achieved molecular downstaging with this regimen.
- || Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Review, Journal: Peptide inhibitors targeting Ras and Ras-associated protein-protein interactions. (Pubmed Central) - Oct 27, 2024
Here we summarize different types of peptide inhibitors, including monocyclic peptides, bicyclic peptides, stapled peptides, and proteomimetic inhibitors, developed in recent years; emphasize the limits and achievements; and discuss the outlook and challenges associated with future research in peptide inhibitors. This review aims to provide a reference for the discovery of Ras peptide inhibitors.
- || Prolia (denosumab) / Amgen
Review, Journal: Osteoarthritis year in review 2024: Epidemiology and therapy. (Pubmed Central) - Oct 27, 2024
Notably, the authors were particularly interested in recent high-quality methodology randomised controlled trials focusing on hand (methotrexate, denosumab, colchicine, topical bethamethasone) and knee OA with conflicting results about stem cells injection. These findings collectively contribute to show the growing burden of OA, but also to help the understanding of OA pathophysiology and inform ongoing efforts to enhance management for people with OA.
- || tapotoclax (AMG 176) / Amgen
P1 data, Journal: A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. (Pubmed Central) - Oct 27, 2024
These findings collectively contribute to show the growing burden of OA, but also to help the understanding of OA pathophysiology and inform ongoing efforts to enhance management for people with OA. No abstract available
- | Ibrance (palbociclib) / Pfizer
Journal: CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response. (Pubmed Central) - Oct 27, 2024
We analyzed the response to the CDK4/6 inhibitor palbociclib in bladder cancer cells over a 48-hour time course using RNA sequencing and identified a multi-step mechanism of response...At later stages during therapy, increased expression of the MiT/TFE protein family leads to lysosomal biogenesis which is essential to maintain this response. Lastly, cancer cells either undergo senescence and apoptosis or develop mechanisms of resistance following CDK4/6 inhibition.
- | Prolia (denosumab) / Amgen
Journal: A Multi-Center Observation Study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients with Osteoporosis, and Other Non-Malignant Bone Diseases, in Northwestern Italy over 16 Years. (Pubmed Central) - Oct 26, 2024
In this study, we describe epidemiological and clinical characteristics of patients, and the drug most frequently involved in MRONJ cases in our region over a long period, allowing a comprehensive view of the progression of the disease. Greater collaboration among specialists is needed for correct and early diagnosis to improve measures potentially reducing disease incidence and to limit quality of life deterioration in patients with osteoporosis and other non-malignant diseases.
- | gedatolisib (PF-05212384) / Celcuity
Preclinical, Journal: Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib. (Pubmed Central) - Oct 26, 2024
Gedatolisib in combination with other therapies has shown an acceptable safety profile and promising preliminary efficacy in clinical studies with various solid tumor types. The non-clinical data presented here support the development of gedatolisib combined with CDK4/6 inhibitors and/or hormonal therapy for gynecologic cancer treatment.
- || Imlygic (talimogene laherparepvec) / Amgen
Review, Journal: Ultrasound-guided intra-tumoral administration of directly-injected therapies: a review of the technical and logistical considerations. (Pubmed Central) - Oct 26, 2024
This has relevance to cancer centres, radiology departments, individual radiologists, and other team members with a future role in meeting the emerging need for these procedures. This paper provides advice on developing such an imaging service, and offers certain insights into the evolving remit of radiologists within cancer care in the near future.
- | Repatha (evolocumab) / Amgen, Astellas
Observational data, Journal, Real-world evidence, Real-world: Asia-Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study. (Pubmed Central) - Oct 26, 2024
Real-world, Asia-Pacific data showed that LDL-C reduction after initiating evolocumab was consistent with that observed in other clinical trials and patient populations. Graphical abstract available for this article.
- | Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Journal, CAR T-Cell Therapy: Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches. (Pubmed Central) - Oct 25, 2024
Conclusively, we have designed and developed a dual targeting (MSLN & CEA) CAR protein towards KRAS-mutated PDAC using computational approaches. Alongside, we further recommend to engineer this designed CAR in T-cells and evaluating their therapeutic efficiency in in vitro and in vivo studies in the near future.
- ||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Clinical, Journal, Adverse events: Teprotumumab for the Treatment of Thyroid Eye Disease: Why Should We Keep Our Eyes "Wide Open"?-A Clinical and Pharmacovigilance Point of View. (Pubmed Central) - Oct 25, 2024
Teprotumumab is undoubtedly a major treatment option in TED. However, before prescribing a drug, practitioners should assess its benefit/risk ratio based on the following: (i) evidence-based medicine; (ii) their empirical experience; (iii) the cost/benefit analysis; (iv) the long-term outcomes and safety profile.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Retrospective data, Journal: Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume. (Pubmed Central) - Oct 25, 2024
This study highlights that patients with MCV delta > 10 had longer median progression-free survival compared to those with MCV delta ? 10.
- || Enbrel (etanercept) / Pfizer, Amgen
Retrospective data, Review, Journal: The role of neutrophils in pain: systematic review and meta-analysis of animal studies. (Pubmed Central) - Oct 25, 2024
In conclusion, the contribution of neutrophils to pain depends on pain etiology (experimental model), pain outcome, and the neutrophil depletion strategy. Further research is needed to improve our understanding on the mechanisms of these differences.
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Journal: Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia. (Pubmed Central) - Oct 25, 2024
The minimal residual disease (MRD) was 0.08% on day 28, and InO was continued, thus achieving MRD negativity; the patient successfully underwent an allogeneic stem cell transplantation from a matched family donor. Our case highlights the efficacy and safety of InO as a salvage treatment in the setting of relapsed B-ALL refractory not only to conventional chemotherapy but also to novel treatments, such as blinatumomab and bortezomib.
- | Prolia (denosumab) / Amgen
Journal: Atypical presentation of PJP: hypercalcemia and kidney injury in an allogeneic stem cell transplant recipient. (Pubmed Central) - Oct 25, 2024
- || Neulasta (pegfilgrastim) / Roche, Neumax (filgrastim biosimilar) / Fresenius Kabi, Stimufend (pegfilgrastim-fpgk) / Fresenius Kabi
Clinical, Journal: Demonstration of physicochemical and functional similarity between Stimufend (pegfilgrastim-fpgk) and Neulasta (pegfilgrastim): A comparative analytical assessment. (Pubmed Central) - Oct 24, 2024
Our case highlights the efficacy and safety of InO as a salvage treatment in the setting of relapsed B-ALL refractory not only to conventional chemotherapy but also to novel treatments, such as blinatumomab and bortezomib. The findings of this study provide robust evidence supporting the structural and functional biosimilarity between Stimufend
- | Prolia (denosumab) / Amgen
Journal: Evaluation of Osteogenic Phenotype in Postmenopausal Women receiving Anabolic and Antiresorptive Osteoporosis Therapies. (Pubmed Central) - Oct 24, 2024
Since concomitant therapy with denosumab and teriparatide has shown promise in this respect, investigations were undertaken to explore whether the changes in osteogenic phenotype could provide insight into the cellular and molecular mechanism of this effect...This was associated with an increased in bone marrow stromal cell expression of LGR6 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 6), a stem cell marker and activator of the canonical Wnt signaling pathway. These data suggest that enhancement of canonical Wnt signaling contributes to the increase in osteoprogenitors and consequently an increase in bone density in postmenopausal women receiving combination therapy for osteoporosis.
- || Prolia (denosumab) / Amgen
Review, Journal: Exploring Denosumab's potential in aneurysmal bone cyst treatment: A scoping review. (Pubmed Central) - Oct 24, 2024
Concerns exist about tumour recurrence and rebound hypercalcemia, necessitating careful monitoring, longer follow-up, and prophylactic measures. Prospective clinical trials are warranted for deeper insights.
- ivabradine / Generic mfg.
Clinical protocol, Journal: Effect of heart rate control with ivabradine on hemodynamic in patients with sepsis: study protocol for a prospective, multicenter, randomized controlled trial. (Pubmed Central) - Oct 24, 2024
P4
There are limited studies on ivabradine to control heart rate in patients with sepsis. Our study aims to evaluate whether direct sinus node inhibition can improve hemodynamics, as well as its impact on organ function and prognosis in patients with sepsis, so as to provide evidence for the safe usage in clinical practice.
- | Prolia (denosumab) / Amgen
Enrollment open, Trial completion date, Trial primary completion date: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (clinicaltrials.gov) - Oct 23, 2024
P=N/A, N=2478, Recruiting, Sponsor: Peking Union Medical College Hospital
Our study aims to evaluate whether direct sinus node inhibition can improve hemodynamics, as well as its impact on organ function and prognosis in patients with sepsis, so as to provide evidence for the safe usage in clinical practice. Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026
- || Imdelltra (tarlatamab-dlle) / Amgen
Trial completion, Trial completion date, Trial primary completion date: DeLLpro-300: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov) - Oct 23, 2024
P1, N=41, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026 Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Jul 2024 | Trial primary completion date: Aug 2025 --> Jul 2024
- ||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Adverse events: Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System. (Pubmed Central) - Oct 23, 2024
Close monitoring of these AEs is crucial. Further studies are necessary to verify the connection between CDK4/6 inhibitors and neurological and psychiatric AEs.
- Imdelltra (tarlatamab-dlle) / Amgen
Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1 (Foyer mezzanine) - Oct 23, 2024 - Abstract #ESMOIO2024ESMO_IO_347;
- || Prolia (denosumab) / Amgen
Review, Journal: Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle. (Pubmed Central) - Oct 23, 2024
Targeting RANKL may be a novel therapy in ameliorating loss of muscle mass and function. More research is warranted to determine the causality of the RANK-RANKL-OPG axis in extra-osseous tissues, especially those affected by aging.
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report. (Pubmed Central) - Oct 23, 2024
However, there is limited experience with the combination of denosumab and romosozumab, which may be an alternative antiresorptive/anabolic regimen for individuals who are not candidates for PTH receptor agonists. In this case, we present a young man with glucocorticoid-induced osteoporosis who could not tolerate a daily injectable anabolic and who experienced improvement in bone mineral density with concurrent denosumab and off-label romosozumab administration.
- || Wezlana (ustekinumab-auub) / Amgen
Clinical, Journal: Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, active-controlled, comparative clinical study over 52 weeks. (Pubmed Central) - Oct 23, 2024
P3
These results indicate that ABP 654 and ustekinumab RP are clinically similar in efficacy, safety, and immunogenicity in patients with moderate-to-severe plaque psoriasis. Further, a single transition from ustekinumab RP to ABP 654 at week 28 had no impact on the efficacy, safety, or immunogenicity results for the remainder of the 52-week study, supporting a conclusion of no clinically meaningful differences between ABP 654 and ustekinumab RP.
- | Journal: Hypersensitivity to the CGRP Inhibitor Monoclonal Antibodies Galcanezumab, Erenumab, and Fremanezumab With Tolerance to Eptinezumab. (Pubmed Central) - Oct 23, 2024
Further, a single transition from ustekinumab RP to ABP 654 at week 28 had no impact on the efficacy, safety, or immunogenicity results for the remainder of the 52-week study, supporting a conclusion of no clinically meaningful differences between ABP 654 and ustekinumab RP. No abstract available
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: EPI-SURVEY: Grade of Awareness Among Spanish Allergists, Hospital Pharmacists, and Pulmonologists of the Relevance of Bronchial Epithelium and Alarmins in the Pathogenesis and Management of Severe Asthma. (Pubmed Central) - Oct 23, 2024
No abstract available No abstract available
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Sex differences in LDL-C reduction response to evolocumab: A propensity score matching analysis. (Pubmed Central) - Oct 23, 2024
No abstract available These results suggest that males have a better response to evolocumab in term of LDL-C reduction compared to females.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarxio (filgrastim-sndz) / Sandoz
Journal, Real-world evidence, Real-world: Real world comparison of filgrastim to filgrastim-sndz in patients with chemotherapy-induced neutropenia. (Pubmed Central) - Oct 23, 2024
These results suggest that males have a better response to evolocumab in term of LDL-C reduction compared to females. filgrastim-sndz significantly reduced healthcare utilization costs compared to reference filgrastim with similar effect on absolute neutrophil count, incidence of fever, and febrile neutropenia.
- | Prolia (denosumab) / Amgen
Journal: IMPC-based screening revealed that ROBO1 can regulate osteoporosis by inhibiting osteogenic differentiation. (Pubmed Central) - Oct 23, 2024
The utilization of denosumab in treating osteoporosis highlights promising prospects for osteoporosis intervention guided by gene targets...Our study provides several novel molecular mechanisms involved in the pathogenesis of osteoporosis. ROBO1 is a potential target for osteoporosis intervention.
- || Nexletol (bempedoic acid) / Esperion Therap, Leqvio (inclisiran) / Novartis
Review, Journal: A Comparative Analysis of Low-Density Lipoprotein Cholesterol (LDL-C)-Lowering Activities of Bempedoic Acid, Inclisiran, and PCSK9 Inhibitors: A Systematic Review. (Pubmed Central) - Oct 23, 2024
Newer LDL-C-lowering drugs show promise in improving lipid profiles, patient compliance, and safety. However, these findings are not conclusive, as other factors also influence treatment choice.
- || Stivarga (regorafenib) / Bayer
PK/PD data, Journal: Bioequivalence and Pharmacokinetic Evaluation of Regorafenib Tablets in Healthy Chinese Volunteers. (Pubmed Central) - Oct 23, 2024
Ingesting high-fat and high-calorie foods increases exposure to regorafenib, leading to slower rates of absorption. The safety profiles of the 2 preparations were similar.
- | Ibrance (palbociclib) / Pfizer, AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas (clinicaltrials.gov) - Oct 23, 2024
P1, N=6, Recruiting, Sponsor: West China Hospital
- || Imdelltra (tarlatamab-dlle) / Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion, Trial completion date: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Oct 23, 2024
P1, N=23, Completed, Sponsor: Amgen
The safety profiles of the 2 preparations were similar. Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Sep 2024
- || Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Metastases: A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer (clinicaltrials.gov) - Oct 23, 2024
P2, N=23, Completed, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Sep 2024 Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Dec 2023
- ||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion: WAYFINDER: Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma (clinicaltrials.gov) - Oct 23, 2024
P3, N=306, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Dec 2023 Active, not recruiting --> Completed
- || olpasiran (AMG 890) / Amgen
Enrollment open: A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants (clinicaltrials.gov) - Oct 22, 2024
P1, N=32, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Clinical, Retrospective data, Review, Journal: Efficacy of modern therapies for heart failure with reduced ejection fraction in specific population subgroups: a systematic review and network meta-analysis. (Pubmed Central) - Oct 22, 2024
Not yet recruiting --> Recruiting Emerging HFrEF therapies show a clinical benefit with the reduction of the primary composite endpoint of CVD and HFH, with each drug being more effective in specific patient population.
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Delivery of Care for Pediatric Patients Receiving Blinatumomab: A Children's Oncology Group Study. (Pubmed Central) - Oct 22, 2024
Emerging HFrEF therapies show a clinical benefit with the reduction of the primary composite endpoint of CVD and HFH, with each drug being more effective in specific patient population. This study describes current institutional practices surrounding administration of 28-day blinatumomab infusions in children with leukemia and offers a starting point for institutional benchmarking and standardization of practice.
- | Repatha (evolocumab) / Amgen, Astellas
Journal, Real-world evidence, Real-world: Real-World Application of Evolocumab Among Patients with Hyperlipidemia in Korea: A Multicenter Prospective Study. (Pubmed Central) - Oct 22, 2024
This study describes current institutional practices surrounding administration of 28-day blinatumomab infusions in children with leukemia and offers a starting point for institutional benchmarking and standardization of practice. Evolocumab treatment was associated with significant LDL-C lowering and favorable safety and guideline-recommended LDL-C goal achievement rates among patients with ACS in the real-world clinical practice setting in South Korea.
- || Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Clinical, Retrospective data, Review, Journal, Metastases: Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - Oct 22, 2024
These findings highlight the need for careful patient selection and monitoring to optimize outcomes. Further studies are warranted to refine strategies for maximizing the therapeutic benefits of anti-EGFR rechallenge.
- || Neulasta (pegfilgrastim) / Roche
Clinical, Observational data, Journal: Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia. (Pubmed Central) - Oct 22, 2024
P
A preference for pegfilgrastim administration via the pen device was observed, though this may have been influenced by the administration sequence and the absence of syringe self-administration. The insights gained can help inform clinical decision-making and improve patient-centered care in managing chemotherapy-induced neutropenia.
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Blinatumomab use in patients with CD19 positive B-ALL and hepatic dysfunction. (Pubmed Central) - Oct 22, 2024
The insights gained can help inform clinical decision-making and improve patient-centered care in managing chemotherapy-induced neutropenia. No abstract available
- | Journal: Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022. (Pubmed Central) - Oct 22, 2024
For b/tsDMARDs, adalimumab is most used and the predominant b/tsDMARD initiated first after csDMARDs. Patterns in DMARD use for JIA have evolved relative to multiple factors, including regulatory approvals and tolerability.
- | Stivarga (regorafenib) / Bayer
Journal, PARP Biomarker: Regorafenib promotes antitumor progression in melanoma by reducing RRM2. (Pubmed Central) - Oct 22, 2024
Patterns in DMARD use for JIA have evolved relative to multiple factors, including regulatory approvals and tolerability. Ultimately, regorafenib significantly inhibits tumor growth in
- || Retrospective data, Review, Journal: Falls and fractures in men with prostate cancer taking second-generation androgen receptor antagonists: A retrospective chart review. (Pubmed Central) - Oct 22, 2024
This could be due to the small patient population or the patient's comorbidities such as osteoporosis, bone metastases, or neuropathy. Fall/fracture risk with enzalutamide and other risk factors for fall and fracture should be considered when discussing treatment and developing a monitoring plan.
- | Tepylute (thiotepa ready to dilute) / Shorla Oncology, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion date: Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma (clinicaltrials.gov) - Oct 22, 2024
P3, N=60, Active, not recruiting, Sponsor: Children's Oncology Group
Fall/fracture risk with enzalutamide and other risk factors for fall and fracture should be considered when discussing treatment and developing a monitoring plan. Trial completion date: Dec 2024 --> Dec 2025
- || onCARlytics (CF33-CD19) / Imugene, VAXinia (CF33-hNIS) / Imugene
Enrollment change, Trial completion date, Trial primary completion date: A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS) (clinicaltrials.gov) - Oct 22, 2024
P1, N=33, Recruiting, Sponsor: Imugene Limited
Trial completion date: Dec 2024 --> Dec 2025 N=52 --> 33 | Trial completion date: Sep 2025 --> May 2029 | Trial primary completion date: Sep 2024 --> Jun 2027